Plaudis H, Pupelis G, Zeiza K, Boka V
Department of Surgery, Riga Eastern Clinical University Hospital "Gailezers", Riga, Latvia.
Acta Chir Belg. 2012 Mar-Apr;112(2):131-8. doi: 10.1080/00015458.2012.11680811.
Experience with administration of synbiotics (prebiotics/probiotics) in patients with severe acute pancreatitis (SAP) has demonstrated immunomodulatory capacity. The aim of this trial was evaluation of the feasibility and perspective of early clinical application of oral synbiotic/prebiotic supplements in patients with SAP.
90 SAP patients were enrolled during the period from 2005-2008. Patients were stratified according to the feeding mode. CONTROL (n = 32) group received standard whole protein feeding formula. SYNBIO (n = 30) and FIBRE groups (n = 28) received early (within first 24-48 hours) synbiotic or prebiotic supplements. Oral administration of synbiotics or prebiotics was commenced when patients were able to sip water.
Daily provided average volume and calories of synbiotic/prebiotic blends were smaller compared to the CONTROL, p = 0.001. Oral administration of synbiotic/prebiotic supplements was associated with lower infection rate (pancreatic and peripancreatic necrosis) compared to the CONTROL, (p = 0.03; p = 0.001), lower rate of surgical interventions, p = 0.005, shorter ICU (p = 0.05) and hospital stay (p = 0.03). Synbiotic supplemented enteral stimulation of the gut resulted in reduced mortality rate compared to the CONTROL, p = 0.02.
Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut seems to be a potentially valuable complement to the routine treatment protocol of SAP.
在重症急性胰腺炎(SAP)患者中使用合生元(益生元/益生菌)的经验已证明其具有免疫调节能力。本试验的目的是评估口服合生元/益生元补充剂在SAP患者中早期临床应用的可行性和前景。
2005年至2008年期间纳入90例SAP患者。患者根据喂养方式进行分层。对照组(n = 32)接受标准全蛋白喂养配方。合生元组(n = 30)和纤维组(n = 28)接受早期(最初24 - 48小时内)合生元或益生元补充剂。当患者能够饮水时开始口服合生元或益生元。
与对照组相比,合生元/益生元混合物每日提供的平均量和热量较小,p = 0.001。与对照组相比,口服合生元/益生元补充剂与较低的感染率(胰腺和胰周坏死)相关,(p = 0.03;p = 0.001),手术干预率较低,p = 0.005,ICU住院时间较短(p = 0.05)和住院时间较短(p = 0.03)。与对照组相比,合生元补充的肠道肠内刺激导致死亡率降低,p = 0.02。
早期小剂量口服合生元/益生元补充的肠道肠内刺激似乎是SAP常规治疗方案的潜在有价值补充。